on-demand webcast

Future Proofing Drug Safety: Target Carcinogenicity Risk Assessment Meets ICH S1B(R1) Standards

Enter your details below to watch the webcast


Let's re-imagine the carcinogenicity assessment

In the fast-paced and cost-conscious 'drug to market' race, momentum can be gained by implementing a Weight of Evidence (WoE) to negate unnecessary preclinical testing. We will present results from a collaboration to standardize a procedural framework supporting the ICH S1B(R1) integrated assessment. Specifically, target biology (WoE #1) will be presented.

This is the concise version of the presentation that was originally shared at the 2024 Annual SOT Meeting and ToxExpo.

Frances Hall PhD
Scientific Application Director for In Silico & Translational Science Solutions